This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Virbagen Omega : EPAR - Summary for the public (PDF/39.88 KB)
First published: 08/03/2007
Last updated: 08/03/2007
|Agency product number||
recombinant omega interferon of feline origin
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
|Date of issue of marketing authorisation valid throughout the European Union||
21/09/2018 Virbagen Omega - EMEA/V/C/000061 - IB/0009
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Reduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age.
Treatment of cats infected with feline leukaemia virus (FeLV) and / or feline immunodeficiency virus (FIV), in non-terminal clinical stages, from the age of nine weeks. In a field study conducted, it was observed that there was:
- a reduction of clinical signs during the symptomatic phase (four months);
- a reduction of mortality:
- in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;
- in non-anaemic cats, mortality rate of 50% in cats infected by FeLV was reduced by 20% following treatment with interferon. In cats infected by FIV, mortality was low (5%) and was not influenced by the treatment.